Reality TV star Savannah Chrisley, 28, has received a federal warning from the US Food and Drug Administration (FDA) over 'misleading' claims on her prescription weight loss website, GoodGirlRX. The FDA sent a letter last month after reviewing the site, raising concerns about statements regarding compounded semaglutide and tirzepatide products.
The FDA took issue with phrases such as 'FDA-approved meds,' 'FDA-approved options' and 'clinically proven GLP-1 results,' noting that compounded drug products are not FDA-approved. The letter stated that these claims implied the products had been 'evaluated for safety and effectiveness when they have not.'
Chrisley was informed that the website violated federal law and was given 15 business days to make corrections or face potential legal repercussions. In response, the site has already changed 'clinically proven results' to 'clinically studied results' and added disclaimers stating that the GLP-1 drugs are not FDA-approved.
In a statement to TMZ, Chrisley clarified that the issue was about 'website wording, not patient safety,' adding that there were 'no fines and no disciplinary action.' She expressed pride in helping women access licensed physicians and welcomed the FDA's guidance.
The website offers access to compounded versions of semaglutide (the active ingredient in Ozempic/Wegovy) and tirzepatide (the active ingredient in Mounjaro/Zepbound). Last November, Chrisley revealed on her podcast that she planned to use tirzepatide to lose 25 pounds, citing fewer side effects compared to other weight-loss jabs.
